BridgeBio Reports Strong Q4/FY25 Results, Multiple Phase 3 Successes, and Key NDA Submissions
BBIO has more than doubled off its 52-week low of $28.325.
Summary
BridgeBio Pharma announced its fourth quarter and full year 2025 financial results, highlighted by significant revenue growth from Attruby and positive Phase 3 readouts for three key pipeline assets, positioning the company for multiple NDA submissions in 2026.
Key Events · Product Development and Regulatory · BBIO
-
Strong Commercial Growth for Attruby
Attruby generated $146.0 million in net product revenue for Q4 2025, contributing to $362.4 million for the full year, demonstrating 35% quarter-over-quarter growth and reaching 7,804 unique patient prescriptions.
-
Three Positive Phase 3 Trial Readouts
The company reported successful Phase 3 results for PROPEL 3 (infigratinib for achondroplasia), FORTIFY (BBP-418 for LGMD2I/R9), and CALIBRATE (encaleret for ADH1), marking significant clinical advancements across its pipeline.
-
Multiple NDA Submissions Planned for 2026
BridgeBio is on track to submit NDAs to the FDA for BBP-418 and encaleret in 1H 2026, and for infigratinib in 2H 2026, with potential U.S. launches anticipated in late 2026/early 2027.
-
Solid Financial Position and Recent Financing
The company ended 2025 with $587.5 million in cash, cash equivalents, and marketable securities, further bolstered by the issuance of $632.5 million in convertible notes in January 2026, positioning it to fund planned operations.
Analysis · BBIO · Life Sciences
BridgeBio Pharma's latest 8-K filing details robust commercial performance for Attruby, alongside a series of highly positive clinical milestones. The successful Phase 3 readouts for infigratinib, BBP-418, and encaleret significantly de-risk the pipeline and set the stage for multiple New Drug Application (NDA) submissions in 2026. This strong execution on both commercial and development fronts provides a clear path to potential new product launches and revenue streams, reinforcing the company's growth trajectory in genetic conditions.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBIO was trading at $73.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $28.33 to $84.94. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.